RUNX1 and metabolic disease: In summary, our findings provided in vivo evidence that adipocyte-enriched lncRNAs (Lnc-FR332443) effectively suppress adipogenesis by targeting Runx1 as well as p38-MAPK and ERK1/2-MAPK, which might provide a new therapeutic target for epigenetic drug intervention to combat the imminent epidemic of obesity and its related metabolic diseases.